ESMO Open 2022 Jun 24;7(4):100519. Epub 2022 Jun 24.
Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria. Electronic address:
Background: Gastroesophageal adenocarcinoma is a major contributor to global disease burden with poor prognosis even in resectable, regionally limited stages. Feasible prognostic tools are crucial to improve patient management, yet scarce.
Patients And Methods: Disease-related symptoms, patient, tumour, treatment as well as laboratory parameters at initial diagnosis and overall survival (OS) of patients with stage II and III gastroesophageal adenocarcinoma, who were treated between 1990 and 2020 at the Medical University of Vienna, were evaluated in a cross-validation model to develop a feasible risk prediction score. Read More